MBMontserrat Balsells

Montserrat Balsells

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Montserrat Balsells has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glycemic control and maternal and fetal outcomes in pregnant women with type 1 diabetes according to the type of basal insulin

    by A. Chico, L. Herranz, R. Corcoy, O. Ramírez, M.M. Goya, J. Bellart, S. González-Romero, M. Codina, P. Sánchez, A. Cortázar, et al.


  • Glibenclamide, Metformin, and Insulin for the Treatment of Gestational Diabetes

    by M. Balsells, A. García-Patterson, I. Solà, M. Roqué, I. Gich, R. Corcoy

  • Ultrasound‐guided compared to conventional treatment in gestational diabetes leads to improved birthweight but more insulin treatment: systematic review and meta‐analysis

    by Montserrat Balsells, Apolonia García‐Patterson, Ignasi Gich, Rosa Corcoy

    ObjectiveTo perform a systematic review and meta-analysis of randomized controlled trials assessing ultrasound-guided versus conventional management in women with a broad severity-spectrum of gestational diabetes mellitus. DesignSystematic review and meta-analysis of trials published until August 2012. SettingPubMed and Web of Science databases. Study selection and methodsEighteen studies were reviewed in full text. Eligibility criteria were (i) randomized controlled trials comparing metabolic management in women with gestational diabetes mellitus and ultrasound-based vs. the conventional management to assess fetal growth, (ii) representative of the whole spectrum of hyperglycemia and fetal growth, (iii) data on perinatal outcomes. Review Manager 5.0 was used to summarize the results. ResultsTwo studies fulfilled inclusion criteria. The ultrasound-guided group had a lower rate of large-for-gestational age newborns (relative risk 0.58, 95% confidence interval 0.34-0.99), macrosomia (relative risk 0.32, 95% confidence interval 0.11-0.95) and abnormal birthweight (small/large-for-gestational age, relative risk 0.64, 95% confidence interval 0.45-0.93) and a higher rate of insulin treatment (relative risk 1.58, 95% confidence interval 1.14-2.20). The number of women with gestational diabetes with a need to treat to prevent an additional newborn with abnormal birthweight was 10. ConclusionsIn women with a broad severity-spectrum of gestational diabetes mellitus, ultrasound-guided management improves birthweight distribution, but increases the need for insulin treatment. More research is needed in this area because results are derived from a limited number of patients.


  • Major congenital malformations in women with gestational diabetes mellitus: a systematic review and meta‐analysis

    by Montserrat Balsells, Apolonia García‐Patterson, Ignasi Gich, Rosa Corcoy

    Background: The risk of major congenital malformations (MCM) is increased in women with pregestational diabetes mellitus (PGDM). Whether this risk is increased in gestational diabetes mellitus (GDM) is still debated. The aim of this study was to perform a systematic review (and meta‐analysis) of major congenital malformations in women with gestational diabetes versus a reference population.Methods: We conducted a MEDLINE search (1 January 1995 to 31 December 2009) of original studies reporting data on major congenital malformations in women with gestational diabetes and a reference group. Information on pregestational diabetes was collected when available. Two investigators considered studies for inclusion and extracted data; discrepancies were solved by consensus. Meta‐analysis tools were used to summarize results. MOOSE and PRISMA guidelines were followed.Results: Two case control and 15 cohort studies were selected out of 3488 retrieved abstracts. A higher risk of major congenital malformations was observed in offspring of women with gestational diabetes with the following relative risk (RR)/odds ratios (OR) and 95% confidence intervals (CI): RR 1.16 (1.07–1.25) in cohort studies and OR 1.4 (1.22–1.62) in case control studies. Risk of major congenital malformations was much higher in offspring of women with PGDM than in those of the reference group: RR 2.66 (2.04–3.47) in cohort studies and OR 4.7 (3.01–6.95) in the single case control study providing information.Conclusion: There is a slightly higher risk of major congenital malformations in women with gestational diabetes than in the reference group. The contribution of women with overt hyperglycemia and other factors could not be ascertained. This risk, however, is much lower than in women with pregestational diabetes. Copyright © 2011 John Wiley & Sons, Ltd.


  • Miscarriage and Malformations

    by Montserrat Balsells, Apolonia García-Patterson, Rosa Corcoy

  • Open Access

    Maternal and Fetal Outcome in Women with Type 2VersusType 1 Diabetes Mellitus: A Systematic Review and Metaanalysis

    by Montserrat Balsells, A. García-Patterson, I. Gich, R. Corcoy

    Context: Glycemic disturbance is usually less severe in pregnant women with type 2 than in those with type 1 diabetes mellitus (DM). Nevertheless, a worse perinatal outcome in women with type 2 DM has been reported in some studies. Objective: Our objective was to review maternal and fetal outcomes in pregnant women with type 2 vs. type 1 DM. Study Selection: We conducted a systematic review of papers providing original data on pregnancy outcomes in both type 2 and type 1 DM (Medline search of the period January 1, 1987, to June 30, 2008). Two independent investigators considered papers for eligibility, and a third one solved discrepancies. Data Extraction: Metaanalysis tools were used to compare four main outcomes (major congenital malformations, stillbirth, and neonatal and perinatal mortality) and 15 secondary ones (five maternal, 10 fetal). Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were used to assess quality. Data Synthesis: Thirty-three studies qualified for inclusion of 3743 citations retrieved. Women with type 2 DM had lower glycated hemoglobin (HbA1c) at booking and throughout pregnancy but a higher risk of perinatal mortality [odds ratio (OR) 1.50, 95% confidence interval (CI) 1.15–1.96] without significant differences in the rates of major congenital malformations, stillbirth, and neonatal mortality. As to secondary outcomes, women with type 2 DM had less diabetic ketoacidosis (OR 0.09, 95% CI 0.02–0.34) and cesarean section (OR 0.80, 95% CI 0.59–0.94) without differences in other outcomes. Conclusions: Despite a milder glycemic disturbance, women with type 2 DM had no better perinatal outcomes than those with type 1, indicating that type 2 DM in pregnancy is a serious condition. Despite lower HbA1c, women with type 2 diabetes mellitus have similar, if not worse, fetal outcomes than those with type 1 diabetes.


    • 1 October 2000
      • Vol. 13  (5) , 257-62

    Gestational diabetes mellitus: metabolic control during labour.

    by M Balsells, R Corcoy, J M Adelantado, A García-Patterson, O Altirriba, A De Leiva

    The purpose of this study was to assess, in women with gestational diabetes mellitus (GDM): 1) metabolic control during labour using a standardised protocol; 2) the influence of therapy during pregnancy in intrapartum metabolic control and insulin requirements; and 3) the impact of maternal glycaemia during labour on neonatal hypoglycaemia. An observational study of 85 women with GDM (54 insulin-treated) was performed. Intrapartum metabolic management included i.v. glucose and insulin infusions, urinary ketone measurement and hourly capillary blood glucose (CBG) monitoring. Mean CBG from arrival to delivery was 4.7 +/- 1.1 mmol/l with 83% of mean CBG values within the target range (2.8-6.9 mmol/l). Mean CBG and insulin requirements were unrelated to therapy during pregnancy, but hypoglycaemia (CBG<2.8 mmol/l) was more frequent in women receiving insulin during pregnancy (40.7 vs 19.4 %, p<0.01). In several logistic regression models, CBG during labour was predictive of neonatal hypoglycaemia. We conclude that in women with GDM, the use of a standardised intrapartum management protocol is associated to fair metabolic control, that insulin requirements during labour are unrelated to therapy during pregnancy and that high CBG during labour increases the risk of neonatal hypoglycaemia.